TAXOTERE

Quốc gia: Israel

Ngôn ngữ: Tiếng Anh

Nguồn: Ministry of Health

Thành phần hoạt chất:

DOCETAXEL AS TRIHYDRATE 20 MG / 1 ML

Sẵn có từ:

SANOFI - AVENTIS ISRAEL LTD

Mã ATC:

L01CD02

Dạng dược phẩm:

CONCENTRATE FOR SOLUTION FOR INFUSION

Tuyến hành chính:

I.V

Sản xuất bởi:

SANOFI - AVENTIS DEUTSCHLAND GMBH, GERMANY

Nhóm trị liệu:

DOCETAXEL

Chỉ dẫn điều trị:

Breast cancer: Taxotere (docetaxel) in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node- positive breast cancer. Taxotere (docetaxel) in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition. Taxotere(docetaxel) monotherapy is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent. Taxotere (docetaxel) in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumors overexpress HER2 and who previously have not received chemotherapy for metastatic disease. Taxotere (docetaxel) in combination with capecitabine is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic chemotherapy.

Ngày ủy quyền:

2012-11-01